All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The Psoriasis and Psoriatic Arthritis Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Psoriasis and Psoriatic Arthritis Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Psoriasis and Psoriatic Arthritis Hub cannot guarantee the accuracy of translated content. The Psoriasis and Psoriatic Arthritis Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

What’s new in PsA at EULAR 2022?

Aug 5, 2022
Learning objective: After reading this article, learners will be able to cite a new clinical development in psoriatic arthritis.

During the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress, the Psoriasis and Psoriatic Arthritis Hub was pleased to speak to Laura Coates, University of Oxford, Oxford, UK. We asked, What’s new in psoriatic arthritis (PsA) at EULAR 2022?

What’s new in PsA at EULAR 2022?

Coates summarized safety and outcome data from several studies that were presented at EULAR, including the COMPLETE-PsA study, as well as two studies that investigated bimekizumab. In addition, Coates discusses potential considerations when deciding which patients are suitable for treatment with a JAK inhibitor.


Subscribe to get the best content related to psoriasis and psoriatic arthritis delivered to your inbox